- Home
- PRQR vs DRUG Comparison
PRQR vs DRUG Comparison
Compare PRQR & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- DRUG
- Stock Information
- Founded
- PRQR 2012
- DRUG 2019
- Country
- PRQR Netherlands
- DRUG United States
- Employees
- PRQR N/A
- DRUG N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- DRUG Pharmaceuticals and Biotechnology
- Sector
- PRQR Health Care
- DRUG Health Care
- Exchange
- PRQR Nasdaq
- DRUG Nasdaq
- Market Cap
- PRQR 179.1M
- DRUG 199.7M
- IPO Year
- PRQR 2014
- DRUG N/A
- Fundamental
- Price
- PRQR $2.13
- DRUG $28.01
- Analyst Decision
- PRQR Strong Buy
- DRUG Strong Buy
- Analyst Count
- PRQR 8
- DRUG 7
- Target Price
- PRQR $8.88
- DRUG $83.25
- AVG Volume (30 Days)
- PRQR 362.3K
- DRUG 52.7K
- Earning Date
- PRQR 08-07-2025
- DRUG 08-13-2025
- Dividend Yield
- PRQR N/A
- DRUG N/A
- EPS Growth
- PRQR N/A
- DRUG N/A
- EPS
- PRQR N/A
- DRUG N/A
- Revenue
- PRQR $21,212,711.00
- DRUG N/A
- Revenue This Year
- PRQR N/A
- DRUG N/A
- Revenue Next Year
- PRQR N/A
- DRUG N/A
- P/E Ratio
- PRQR N/A
- DRUG N/A
- Revenue Growth
- PRQR 85.91
- DRUG N/A
- 52 Week Low
- PRQR $1.07
- DRUG $0.93
- 52 Week High
- PRQR $4.62
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- PRQR 64.73
- DRUG 51.33
- Support Level
- PRQR $1.89
- DRUG $23.18
- Resistance Level
- PRQR $2.54
- DRUG $26.86
- Average True Range (ATR)
- PRQR 0.14
- DRUG 1.85
- MACD
- PRQR 0.01
- DRUG 0.11
- Stochastic Oscillator
- PRQR 43.06
- DRUG 78.30
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.